Emil Kumar
Impact in
-
- COVID-19 and healthcare impacts
- CAR-T cell therapy research
-
- Cancer Genomics and Diagnostics
Papers in
-
- Lymphoma Diagnosis and Treatment 8
- Oncology 8
- CAR-T cell therapy research 4
- Viral-associated cancers and disorders 3
- COVID-19 and healthcare impacts 1
- Co-authors
- Koorosh Korfi (3 shared papers)Findlay Bewicke‐Copley (2 shared papers)Giuseppe Palladino (2 shared papers)Jun Wang (2 shared papers)Jessica Okosun (7 shared papers)Jude Fitzgibbon (3 shared papers)Asim Khwaja (1 shared paper)Kwee Yong (1 shared paper)
- Journals
- British Journal of Haematology (4 papers)Hematology/Oncology Clinics of North America (1 paper)Frontiers in Oncology (1 paper)HemaSphere (1 paper)Current Opinion in Hematology (1 paper)
- Partner nations
- United KingdomUnited StatesGermany
In The Last Decade
Emil Kumar
10 papers receiving 207 citations
Peers
Comparison fields: 5 of 51
- Oncology 75
- Cancer Research 40
- Pathology and Forensic Medicine 45
- Infectious Diseases 42
- Genetics 12
Countries citing papers authored by Emil Kumar
This map shows the geographic impact of Emil Kumar's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Emil Kumar with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Emil Kumar more than expected).
Fields of papers citing papers by Emil Kumar
This network shows the impact of papers produced by Emil Kumar. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Emil Kumar. The network helps show where Emil Kumar may publish in the future.
Co-authors
The 25 scholars most cited alongside Emil Kumar, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2019 | 94 | |
| 2 | 2020 | 49 | |
| 3 | 2021 | 26 | |
| 4 | 2015 | 20 | |
| 5 | 2020 | 8 | |
| 6 | 2018 | 6 | |
| 7 | 2025 | 1 | |
| 8 | 2024 | 1 | |
| 9 | 2019 | 1 | |
| 10 | 2022 | 1 | |
| 11 | 2025 | 0 | |
| 12 | 2026 | 0 |
About Emil Kumar
Emil Kumar is a scholar working on Pathology and Forensic Medicine, Oncology, Infectious Diseases, Molecular Biology and Dermatology, having authored 12 papers that have together received 207 indexed citations. Recurring topics across this work include Lymphoma Diagnosis and Treatment (8 papers), CAR-T cell therapy research (4 papers), Viral-associated cancers and disorders (3 papers), Cancer Genomics and Diagnostics (2 papers), Dermatological and COVID-19 studies (1 paper), Genomics and Rare Diseases (1 paper), COVID-19 and healthcare impacts (1 paper) and Ovarian cancer diagnosis and treatment (1 paper). The work is most often cited by research in Oncology (75 citations), Cancer Research (40 citations), Pathology and Forensic Medicine (45 citations), Infectious Diseases (42 citations) and Genetics (12 citations). Emil Kumar has collaborated with scholars based in United Kingdom, United States and Germany. Frequent co-authors include Koorosh Korfi, Findlay Bewicke‐Copley, Giuseppe Palladino, Jun Wang, Jessica Okosun, Jude Fitzgibbon, Asim Khwaja, Kwee Yong, Mervyn Singer and Kirit M. Ardeshna. Their work appears in journals such as British Journal of Haematology, Hematology/Oncology Clinics of North America, Frontiers in Oncology, HemaSphere and Current Opinion in Hematology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.